It’s been more than 4 years since Shinya Yamanaka published the remarkable finding that his lab could transform or “reprogram” regular cells called fibroblasts into a very unique state that was quite similar to that of embryonic stem cells (ESC). Yamanaka called these new cells “iPS cells” for induced pluripotent stem cells. Since that time, …
If a stem cell could talk, what would it say or tweet? I imagine stem cells like teenagers. So much potential but at times difficult or unpredictable. Below is my take on what a stem cell being prepared for transplantation would Tweet. Life is too short to always take everything 100% seriously so here’s some …
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to …
Challenges translating stem cell treatments to patients Read More »
If IPS cells are not ready for prime time, it is probably due to these three critical challenges for these amazing cells. TUMORIGENICITY Those of us who work with IPS cells are very excited about their potential for use in regenerative medicine therapies. One serious hurdle we have talked about in the past is tumorigenicity. …
Not ready for prime time: the three critical challenges for IPS cells Read More »
One question I am frequently asked by readers and colleagues is “what other stem cell blogs or bloggers can you recommend that are written by a stem cell scientist and updated on a regular basis?” The simple but surprising answer: there are none. It’s lonely out here in cyberspace! (2020 update: The good news today …
How many scientist bloggers does it take to change a light bulb? Read More »
CIRM Board Member, Jeff Sheehy, has a wonderful piece in Nature Medicine on why patient advocates play a critical role in decision making on research priorities (hat tip to Amy Adams who first blogged on Sheehy’s piece). Patient advocates bring a unique and valuable perspective to the table. Their role in guiding CIRM research funding …
Why scientists must be advocates too: Jeff Sheehy Read More »
Dr. James Sherley, the scientist behind the lawsuit against federally-funded ES cell research, has penned an opinion piece in The Daily Caller today calling on NIH to, in his words, ‘do the right thing.’ However, what Sherley is really asking is for the NIH, other stem cell scientists, and all Americans to think like he …
James Sherley of anti-ESC lawsuit calls on NIH to think like he does Read More »
Here an anonymous stem cell scientist frankly answers questions about the field in an interview with me. Of course I have to ask you about the recent U.S. court ruling essentially declaring all federal funding of human ES cell work illegal. What’s your take on this? ANSWER: The ruling has so many flaws in it. …
Anonymous stem cell scientist frankly answers questions about the field Read More »